Drug Database · Clinicians

Methyldopa

Brands (28) Dopacare, Dopalink, Dopamaine…Show all

Antihypertensive (centrally acting antiadrenergic agent); Centrally acting antihypertensive (alpha-2 adrenoceptor agonist); and others PH FDA category

Rx · Prescription drug38 PH productsPNF-listedPhilHealth GAMOTVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID e1114a58-9ab5-486e-85ed-360365b06396, version date March 26, 2025 (Methyldopa · Chartwell RX, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATION AND USAGE Hypertension.
US FDA label
Full indications and usage US FDA label

INDICATION AND USAGE Hypertension.

Contraindications

CONTRAINDICATIONS Methyldopa is contraindicated in patients: — with active hepatic disease, such as acute hepatitis and active cirrhosis — with liver disorders previously associated with methyldopa therapy (see WARNINGS) — with hypersensitivity to any component of these products. — on therapy with monoamine oxidase (MAO) inhibitors.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION ADULTS Initiation of Therapy The usual starting dosage of Methyldopa is 250 mg two or three times a day in the first 48 hours. The daily dosage then may be increased or decreased, preferably at intervals of not less than two days, until an adequate response is achieved. To minimize the sedation, start dosage increases in the evening.

By adjustment of dosage, morning hypotension may be prevented without sacrificing control of afternoon blood pressure. When methyldopa is given to patients on other antihypertensives, the dose of these agents may need to be adjusted to effect a smooth transition. When Methyldopa is given with antihypertensives other than thiazides, the initial dosage of Methyldopa should be limited to 500 mg daily in divided doses; when Methyldopa is added to a thiazide, the dosage of thiazide need not be changed.

Maintenance Therapy The usual daily dosage of Methyldopa is 500 mg to 2 g in two to four doses. Although occasional patients have responded to higher doses, the maximum recommended daily dosage is 3 g. Once an effective dosage range is attained, a smooth blood pressure response occurs in most patients in 12 to 24 hours. Since methyldopa has a relatively short duration of action, withdrawal is followed by return of hypertension usually within 48 hours.

This is not complicated by an overshoot of blood pressure. Occasionally tolerance may occur, usually between the second and third month of therapy. Adding a diuretic or increasing the dosage of methyldopa frequently will restore effective control of blood pressure. A thiazide may be added at any time during methyldopa therapy and is recommended if therapy has not been started with a thiazide or if effective control of blood pressure cannot be maintained on 2 g of methyldopa daily.

Methyldopa is largely excreted by the kidney and patients with impaired renal function may respond to smaller doses. Syncope in older patients may be related to an increased sensitivity and advanced arteriosclerotic vascular disease. This may be avoided by lower doses. (See PRECAUTIONS, Geriatric Use) PEDIATRIC PATIENTS Initial dosage is based on 10 mg/kg of body weight daily in two to four doses.

The daily dosage then is increased or decreased until an adequate response is achieved. The maximum dosage is 65 mg/kg or 3 g daily, whichever is less. (See PRECAUTIONS, Pediatric Use)

Dosing: Altered kidney function

From the US FDA label · Dosage and administration (renal excerpts)

Methyldopa is largely excreted by the kidney and patients with impaired renal function may respond to smaller doses.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Film-coated tablet: 250 mg
  • Tablet: 125 mg, 250 mg

Registered products in the Philippines

38 products registered with the Food and Drug Administration (FDA) Philippines list Methyldopa as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products38
Philippine FDA-registered products for Methyldopa
Package insert
AldocoreMethyldopa
250 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's)
RxVAT-exempt
S Kant Health Care LimitedIndia
Greencore Pharma Inc.Importer: Triple Tact Import & Export Corp.
DRP-13139-01
Dec 9, 2027
AldometMethyldopa
250 mg TabletClear PVC/Alu Foil Blister Pack x 10's Box of 100's; Clear PVC/Alu Foil Blister Pack x 10's Box of 500's
RxVAT-exempt
Aspen Sa Operations (Pty) LtdRepublic of South Africa
Aspen Philippines Inc.
DR-XY39311
Apr 12, 2031
AldopiemMethyldopa
250 mg Film-Coated TabletAlu/Clear PVC Film Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Vivilon Pharmaceuticals Inc.
DRP-13715
Mar 31, 2028
AldowellMethyldopa
250 mg Film-Coated TabletAlu/PVDC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
S Kant Healthcare Ltd.India
Wellchem Pharmaceutical Products
DRP-18828
Sep 14, 2031
AldrometMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Aldril Pharmaceuticals, Inc.
DRP-8968
Aug 17, 2030
BP LowMethyldopa
250 mg TabletAlu/Amber PVC Blister Pack x 10's Box of 100's
RxVAT-exempt
S Kant Healthcare LimitedIndia
Ambica International Corporation
DRP-7382
Dec 18, 2029
DomepaMethyldopa
250 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Domesco Medical Import Export Joint-Stock CorporationVietnam
The Cathay Drug Co., Inc.
DR-XY45568
Aug 26, 2031
DopacareMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAlu Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-3655
May 27, 2031
DopacareMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Totalcare Pharma Inc.
DRP-9112
Sep 14, 2030
DopafixMethyldopa
250 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's)
RxVAT-exempt
S Kant Healthcare LimitedIndia
Medvybe Pharmaceutical TradingImporter: Triple Tact Import & Export Corp.
DRP-13139-02
Dec 9, 2027
DopalinkMethyldopa (as Sesquihydrate)
250 mg Film-Coated TabletAlu Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Altomed Pharmaceuticals, Inc.Trader: Totalcare Pharma Inc.
DRP-3655-02
May 27, 2036
DopalinkMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Vitalink Health Products, Inc.
DRP-9110
Sep 14, 2030
DopamaineMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAluminum Strip Foil x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Ultramed Pharma, Inc.Trader: Vamsler Phils., Inc.
DRP-5467-01
Feb 25, 2030
DopamaineMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Trader: Ultramed Pharma, Inc.
DRP-9303
Aug 6, 2031
DopametMethyldopa (as Sesquihydrate)
250 mg Film-Coated TabletAlu-Alu Blister Pack x 8's (Box of 40's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Solvang Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc.
DR-XY32301
Sep 25, 2031
DopametMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Euro-Health Care Exponents, Inc.
DRP-9129
Sep 15, 2030
DoparineMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAluminum Strip Foil x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Vamsler Phils. Incorporated
DRP-5467
Feb 25, 2030
DoparineMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Vamsler Phils. Incorporated
DRP-9109
Sep 14, 2030
DopathylMethyldopa (as Sesquihydrate)
250 mg Film-Coated TabletAlu/Alu Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Meedpharma Medical Supplies & Equipment DistributorTrader: Westfield Pharmaceuticals, Inc.
DRP-8568
Jun 15, 2027
HydometMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletFoil Strip Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Gamot Philippines, Inc.
DRP-5066
Jul 28, 2031
HydometMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Gamot Philippines, Inc.
DRP-9304
Nov 24, 2030
HymetMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-9111
Sep 14, 2030
HypnalMethyldopa
125 mg TabletBlister Pack x 10's (Box of 100's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
Trader: Vonwelt Inc.
DRP-1066
Feb 27, 2027
MedopaMethyldopa
125mg TabletBlister Pack x 10's (Box of 100's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
Drugmaker's Laboratories, Inc.Trader: Vonwelt, Inc.
DRP-1066-03
Feb 27, 2027
MethdosaphMethyldopa
250 mg Film-Coated TabletAluminum Foil Strip Pack x 10's (Box of 100's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.
DRP-14272
Mar 26, 2031
MetidolMethyldopa
125 mg TabletAluminum Foil Strip x 10's Box of 100's
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
—
DRP-10465
Sep 29, 2028
MetilMethyldopa
125 mg TabletBlister Pack x 10's (Box of 100's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Vonwelt Inc.
DRP-1066-02
Feb 27, 2027
MetyenMethyldopa
250 mg TabletAlu/PVC Blister Pack x 10's (Box of 10's and 30's)
RxVAT-exempt
Huazhong Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-17780
Mar 11, 2031
MydopaMethyldopa
250 mg Film-Coated TabletAlu/PVC blister pack x 10’s (Box of 100's)
RxVAT-exempt
S Kant Healthcare LimitedIndia
Triple Tact Import & Export Corp.
DRP-13139
Dec 9, 2027
NoneMethyldopa
250 mg TabletAlu Strip Foil x 10’s Box of 100’s
RxVAT-exempt
Hizon Laboratories, Inc.Philippines
—
DRP-5679
Feb 28, 2029
PrevadopaMethyldopa
250 mg Film-Coated TabletAlu/Clear PVC Film Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-13715-01
Mar 31, 2028
ThylometMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletFoil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Euro-Health Care Exponents, Inc.Trader: Gamot Philippines, Inc.
DRP-5066-02
Aug 18, 2031
TildopaMethyldopa
250 mg TabletAlu/Amber PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
S Kant Healthcare LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-7382-02
Dec 18, 2029
TomedylMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletFoil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Altomed Pharmaceuticals, Inc.Trader: Gamot Philippines, Inc.
DRP-5066-03
Aug 27, 2031
UnbrandedMethyldopa (as sesquihydrate)
250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
—
DRP-9792
Jun 7, 2031
UnbrandedMethyldopa
250 mg TabletAlu/Amber PVC Blister Pack x 10's Box of 100's
RxVAT-exempt
S Kant Healthcare Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-7382-01
Dec 18, 2029
XylodopaMethyldopa
250 mg Film-Coated TabletAlu-PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15934
Oct 2, 2029
(no brand name)Methyldopa
250 mg Film-Coated TabletAlu/Clear PVC Film Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Vivilon Pharmaceuticals, Inc.
DRP-13775
Apr 17, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS It is important to recognize that a positive Coombs test, hemolytic anemia, and liver disorders may occur with methyldopa therapy. The rare occurrences of hemolytic anemia or liver disorders could lead to potentially fatal complications unless properly recognized and managed. Read this section carefully to understand these reactions.

With prolonged methyldopa therapy, 10 to 20 percent of patients develop a positive direct Coombs test which usually occurs between 6 and 12 months of methyldopa therapy. Lowest incidence is at daily dosage of 1 g or less. This on rare occasions may be associated with hemolytic anemia, which could lead to potentially fatal complications.

One cannot predict which patients with a positive direct Coombs test may develop hemolytic anemia. Prior existence or development of a positive direct Coombs test is not in itself a contraindication to use of methyldopa. If a positive Coombs test develops during methyldopa therapy, the physician should determine whether hemolytic anemia exists and whether the positive Coombs test may be a problem.

For example, in addition to a positive direct Coombs test there is less often a positive indirect Coombs test which may interfere with cross matching of blood. Before treatment is started, it is desirable to do a blood count (hematocrit, hemoglobin, or red cell count) for a baseline or to establish whether there is anemia.

Periodic blood counts should be done during therapy to detect hemolytic anemia. It may be useful to do a direct Coombs test before therapy and at 6 and 12 months after the start of therapy. If Coombs-positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued. Usually the anemia remits promptly.

If not, corticosteroids may be given and other causes of anemia should be considered. If the hemolytic anemia is related to methyldopa, the drug should not be reinstituted. When methyldopa causes Coombs positivity alone or with hemolytic anemia, the red cell is usually coated with gamma globulin of the IgG (gamma G) class only.

The positive Coombs test may not revert to normal until weeks to months after methyldopa is stopped. Should the need for transfusion arise in a patient receiving methyldopa, both a direct and an indirect Coombs test should be performed. In the absence of hemolytic anemia, usually only the direct Coombs test will be positive.

A positive direct Coombs test alone will not interfere with typing or cross matching. If the indirect Coombs test is also positive, problems may arise in the major cross match and the assistance of a hematologist or transfusion expert will be needed. Occasionally, fever has occurred within the first 3 weeks of methyldopa therapy, associated in some cases with eosinophilia or abnormalities in one or more liver function tests, such as serum alkaline phosphatase, serum transaminases (SGOT, SGPT), bilirubin, and prothrombin time.

Jaundice, with or without fever, may occur with onset usually within the first 2 to 3 months of therapy. In some patients the findings are consistent with those of cholestasis. In others the findings are consistent with hepatitis and hepatocellular injury. Rarely, fatal hepatic necrosis has been reported after use of methyldopa.

These hepatic changes may represent hypersensitivity reactions. Periodic determinations of hepatic function should be done particularly during the first 6 to 12 weeks of therapy or whenever an unexplained fever occurs. If fever, abnormalities in liver function tests, or jaundice appear, stop therapy with methyldopa. If caused by methyldopa, the temperature and abnormalities in liver function characteristically have reverted to normal when the drug was discontinued.

Methyldopa should not be reinstituted in such patients. Rarely, a reversible reduction of the white blood cell count with a primary effect on the granulocytes has been seen. The granulocyte count returned promptly to normal on discontinuance of the drug. Rare cases of granulocytopenia have been reported. In each instance, upon stopping the drug, the white cell count returned to normal.

Reversible thrombocytopenia has occurred rarely.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. Headache, asthenia, or weakness may be noted as early and transient symptoms. However, significant adverse effects due to Methyldopa have been infrequent and this agent usually is well tolerated.

The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity. Cardiovascular: Aggravation of angina pectoris, congestive heart failure, prolonged carotid sinus hypersensitivity, orthostatic hypotension (decrease daily dosage), edema or weight gain, bradycardia.

Digestive: Pancreatitis, colitis, vomiting, diarrhea, sialadenitis, sore or “black” tongue, nausea, constipation, distension, flatus, dryness of mouth. Endocrine: Hyperprolactinemia. Hematologic: Bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; positive tests for antinuclear antibody, LE cells, and rheumatoid factor, positive Coombs test.

Hepatic: Liver disorders including hepatitis, jaundice, abnormal liver function tests (see WARNINGS). Hypersensitivity: Myocarditis, pericarditis, vasculitis, lupus-like syndrome, drug-related fever, eosinophilia. Nervous System/Psychiatric: Parkinsonism, Bell's palsy, decreased mental acuity, involuntary choreoathetotic movements, symptoms of cerebrovascular insufficiency, psychic disturbances including nightmares and reversible mild psychoses or depression, headache, sedation, asthenia or weakness, dizziness, lightheadedness, paresthesias.

Metabolic: Rise in BUN. Musculoskeletal: Arthralgia, with or without joint swelling; myalgia. Respiratory: Nasal stuffiness. Skin: Toxic epidermal necrolysis, rash. Urogenital: Amenorrhea, breast enlargement, gynecomastia, lactation, impotence, decreased libido.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The known urinary metabolites are: α-methyldopa mono-0-sulfate; 3-0-methyl-α-methyldopa; 3,4-dihydroxyphenylacetone; α-methyldopamine; 3-0-methyl-α-methyldopamine and their conjugates.

Approximately 70% of the drug which is absorbed is excreted in the urine as methyldopa and its mono-0-sulfate conjugate.

The renal clearance is about 130 mL/min in normal subjects and is diminished in renal insufficiency.

The plasma half-life of methyldopa is 105 minutes.

After oral doses, excretion is essentially complete in 36 hours.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Although the mechanism of action has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then lowers arterial pressure by stimulation of central inhibitory alpha-adrenergic receptors, false neurotransmission, and/or reduction of plasma renin activity.

Methyldopa has been shown to cause a net reduction in the tissue concentration of serotonin, dopamine, norepinephrine, and epinephrine. Only methyldopa, the L -isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L -isomer.

About twice the dose of the racemate (DL -alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration.

In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.

Pharmacokinetics and Metabolism The maximum decrease in blood pressure occurs four to six hours after oral dosage. Once an effective dosage level is attained, a smooth blood pressure response occurs in most patients in 12 to 24 hours. After withdrawal, blood pressure usually returns to pretreatment levels within 24-48 hours.

Methyldopa is extensively metabolized. The known urinary metabolites are: α-methyldopa mono-0-sulfate; 3-0-methyl-α-methyldopa; 3,4-dihydroxyphenylacetone; α-methyldopamine; 3-0-methyl-α-methyldopamine and their conjugates. Approximately 70% of the drug which is absorbed is excreted in the urine as methyldopa and its mono-0-sulfate conjugate.

The renal clearance is about 130 mL/min in normal subjects and is diminished in renal insufficiency. The plasma half-life of methyldopa is 105 minutes. After oral doses, excretion is essentially complete in 36 hours. Methyldopa crosses the placental barrier, appears in cord blood, and appears in breast milk.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Methyldopa 250 mg Tablet₱4.86–₱11.00Reference ₱9.18per tabletDPRI procurement range
250 mg tablet₱11.00per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Methyldopa
PNF listingOral: 250 mg tablet
PhilHealth GAMOTYes (listed since July 28, 2025)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Methyldopa · Chartwell RX, LLC [US FDA-approved label, version 3, March 26, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1114a58-9ab5-486e-85ed-360365b06396
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .